Small molecule fluorescent ligands as central nervous system imaging probes

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 5, 2013, Pages 682-696

  Joubert, Jacques ^a   Dyk, Sandra V ^b   Malan, Sarel F ^a  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Fluorescence; Fluorescence spectroscopy; High throughput screening; Imaging agents; Neurochemistry

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; ADENOSINE A1 RECEPTOR; ADRENALIN; AMYLOID BETA PROTEIN; BENZODIAZEPINE RECEPTOR; BENZYLAMINE; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; LIGAND; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; PHENETHYLAMINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SMALL MOLECULE FLUORESCENT LIGAND; TYRAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CONFOCAL LASER MICROSCOPY; DRUG TARGETING; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HUMAN; HUNTINGTON CHOREA; IMAGING; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW;

CENTRAL NERVOUS SYSTEM DISEASES; FLUORESCENT DYES; HUMANS; LIGANDS; MICROSCOPY, FLUORESCENCE; NITRIC OXIDE SYNTHASE; RECEPTOR, ADENOSINE A1; RECEPTORS, DOPAMINE; RECEPTORS, GABA-A; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SEROTONIN; SMALL MOLECULE LIBRARIES;

EID: 84877799679     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313050005     Document Type: Review

References (107)

1. Auer, M.; Moore, K.J.; Myers-Almes, F.J.; Guenther, R.; Pope, A.J.; Stoekli, K.A. Fluorescence correlation spectroscopy: lead discovery by miniaturized HTS. Drug. Disc. Today., 1998, 3, 457-465.
2. McGrath, J.C.; Arribas, S.; Daly, C.J. Fluorescent ligands for the study of receptors. Trends. Pharm., Sci. 1996, 17, 393-399.
3. Daly, C.J.; McGrath, J.C. Fluorescent ligands, antibodies, and proteins for the study of receptors. Pharm. Therap., 2003, 100, 101-118.
4. McCabe, R.T.; Newman, A.H.; Skolnick, P.; AHN 683: a fluorescent ligand for peripheral-type benzodiazepine receptors. J. Pharm. Exp. Terap., 1992, 262(2), 734-740.
5. Snyder, S.H.; Drug and neurotransmitter receptors. New perspectives with clinical relevance. J. Am. Med. Assoc., 1989, 261, 3126-3129.
6. Olsen, R.W.; McCabe, R.T.; Wamsley, J.K. GABAA receptor subtypes: autoradiographic comparison of GABA, benzodiazepine, and convulsant binding sites in the rat central nervous system. J. Chem. Neuroanat., 1990, 3, 59-76.
7. Wulfkuhle, J.D.; Edminston, K.H.; Liotta, L.A.; Petricoin, E.F. Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. Nat. Clin. Pract. Onc., 2006, 3, 256-268.
8. Leung, L.L. Role of thrombospondin in platelet aggregation. J. Clin. Invest. 1984, 74(5), 1764-1772.
9. Baindur, N.; Triggle, D.J. Selective fluorescent ligands for pharmacological receptors. Drug. Dev. Res., 1994, 33, 373-398.
10. Baindur, N.; Triggle, D.J. Concepts and progress in the development of receptor-specific fluorescent ligand. Med. Res. Rev., 1994, 14, 591-664.
11. Leopoldo, M.; Lacivita, E.; Berardi, F.; Perrone, R. Developments in fluorescent probes for receptor research. Drug. Discov. Today. 2009, 14, 709-712.
12. Tairi, A.P.; Hovius, R.; Pick, H.; Blasey, H.; Bernard, A.; Surprenant, A.; Lunstrom, K.; Vogel, H. Ligand binding to the serotonin 5HT3 receptor studied with a novel fluorescent ligand. Biochem. 1998, 37, 15850-15864.
13. Madsen, B.W.; Beglan, C.L.; Spivak, C.E. Fluorescein-labeled naloxone binding to mu opioid receptors on live Chinese hamster ovary cells using confocal fluorescent microscopy. J. Neurosci. Methods. 2000, 97, 123-131.
14. Beaudet, A.; Nouel, D.; Stroh, T.; Vandenbulcke, F.; Dal-Farra, C.; Vincent, J.P. Fluorescent ligands for studying neuropeptide receptors by confocal microscopy. Braz. J. Med. Biol. Res. 1998, 31, 1479-1489.
15. Terrillon, S.; Cheng, L.L.; Stoev, S.; Mouillac, B.; Barberis, C.; Manning, M.; Durroux, T. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J. Med. Chem. 2002, 45, 2579-2588.
16. Turcatti, G.; Zoffmann, S.; Lowe, J.A.; Drozda, S.E.; Chassaing, G.; Schwartz, T.W.; Chollet, A. Characterization of non-peptide antagonist and peptide agonist binding sites of the NK1 receptor with fluorescent ligands. J. Biol. Chem. 1997, 272, 21167-21175.
17. Turcatti, G.; Nemeth, K.; Edgerton, M.D.; Meseth, U.; Talabot, F.; Peitsch, M.; Knowles, J.; Vogel, H.; Chollet, A. Probing the structure and function of the tachykinin neurokinin-2 receptor through biosynthetic incorporation of fluorescent amino acids at specific sites. J. Biol. Chem. 1996, 271, 19991-19998.
18. Macchia, M.; Salvetti, F.; Bertini, S.; Di Bussolo, V.; Gattuso, L.; Gesi, M.; Hamdan, M.; Klotz, N.K.; Laragione, T.; Lucacchini, A; Minutolo, F.; Nencetti, S.; Papi, C.; Tuscano, D.; Martini, C. 7-Nitrobenzofurazan (NBD) derivatives of 5'-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A(3) adenosine receptors. Bioorg. Med. Chem. Lett. 2001, 11, 3023-3026.
19. Hadrich, D.; Berthold, F.; Steckhan, E.; Bonisch, H. Synthesis and characterization of fluorescent ligands for the norepinephrine transporter: potential neuroblastoma imaging agents. J. Med. Chem. 1999, 42, 3101-3108.
20. Chen, H.; Chung, N.N.; Lemieux, C.; Zelent, B.; Vanderkooi, J.M.; Gryczynski, I.; Wilkes, B.C.; Schiller, P.W. [Aladan3]TIPP: a fluorescent delta-opioid antagonist with high delta-receptor binding affinity and delta selectivity. Biopolymers. 2005, 80, 325-331.
21. Vazquez, M.E.; Blanco, J.B.; Salvadori, S.; Trapella, C.; Argazzi, R.; Bryant, S.D.; Jinsmaa, Y.; Lazarus, L.H.; Negri, L.; Giannini, E.; Lattanzi, R.; Colucci, M.; Balboni, G. 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta-and mu-selective opioid peptides. J. Med. Chem. 2006, 49, 3653-3658.
22. Petersen, M.D.; Boye, S.V.; Nielsen, E.H.; Willumsen, J.; Sinning, S.; Wiborg, O.; Bols, M. Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg. Med. Chem., 2007, 15, 4159-4174.
23. Haugland, J.G.; Gregory, J.; Spence, M.T.Z.; Johnson, I.; Miller, E. Handbook of fluorescent probes and research products. USA: Molecular probes. 2002.
24. Brown, S.B. An Introduction to Spectroscopy for Biochemists; Academic Press: London, 1980.
25. Campbell, I.D.; Dwek, R.A. Biological Spectroscopy; The Benjamin/Cummings Publishing Co. Inc., 1984.
26. Song, I.; Hennink, E.J.; Young, I.T.; Tanke, H.J. Photobleaching kinetics of fluorescein in quantitative fluorescence microscopy. Biophys. J. 1995, 68, 2588-2600.
27. Song, I.; Varma, J.W.; Verhoeven, J.W.; Tanke, H.J. Influence of the triplet excited state on the photobleaching kinetics of fluorescein in microscopy. Biophys. J. 1996, 70, 2959-2968.
28. Herman, B. Fluorescence Microscopy; 2nd ed.; BIOS Scientific Publishers: Oxford, UK, 1998.
29. Dobrucki, J. Fluorescence and confocal microscopy. [Web]http://helios.mol.uj.edu.pl/conf_c/moun.html. 2003.
30. Axzelrod, D.; Herman, B.; Centonza, V. E.; Murphy, D.B.; Piston, D.W.; Hardee, C.; kinoshita, R.; Wakefield, T.; Johnson, J.; Erogan, T.; Abramowitz, M.; Fester, K.W.; Kawano, Y.; Enders, R.G.; Spring, K.R.; Parry-Hill, M.J.; Fellers, T.J.; Claxton, N.S.; Davidson, M.W. Fluorescence Microscopy. [Web]http://icecube.berkeley.edu/-bramall/work/astrobiology/fluorescence.html. 2005.
31. Paddock S.; Optical Sectioning-Slices of Life. Science., 2002, 295, 1319-1321.
32. Gunsekera, T.S.; Veal, D.A.; Attfield, P.V. Potential for broad applications of flow cytometry and fluorescence techniques in microbiological and somatic cell analyses of milk. International Journal of Food Microbiology., 2003, 85, 269-279.
33. Robinson, J.P. The Principles of Confocal Microscopy: Components of the Microscope. [Web]http://www.cyto.purdue.edu/flowcyt/educate/pptslide.html. 2005.
34. Gu, M.T.; Tannous, T.; Sheppard, C.J.R. Improved axial resolution in confocal fluorescence microscopy using annular pupils. Optics Communications., 1994, 110, 533-539.
35. Abdulatif, Y.; Hanad, J.P.; Wicksted, G.S.; Dixon, S.; deRochemont, L.P. Laser-induced transient and permanent gratings in Eu3+-doped dual alkaline earth silicate glasses. Journal of Non-Crystalline Solids., 1998, 241, 59-70.
36. Yates, A.S.; Doughty, S.W.; Kendall, D.A.; Kellam, B. Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor. Bioorg. Med. Chem. 2005, 15, 3758-3762.
37. Balboni, G.; Salvadori, S.; Dal Piaz, A.; Bortolotti, F.; Argazzi, R.; Negri, L.; Lattanzi, R.; Bryant, S.D.; Jinsmaa, Y.; Lazarus, L.H. Highly selective fluorescent analog of the potent delta-opioid receptor antagonist Dmt-Tic. J. Med. Chem. 2004, 47, 6541-6546.
38. Cha, J.H.; Zou, M.; Adkins, E.M.; Rasmussen, S.G.F.; Loland, C.J.; Schoenenberger, B.; Gether, U.; Newman, A.H. Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogs as high-affinity fluorescent probes for the dopamine transporter. J. Med. Chem. 2005, 48, 7513-7516.
39. Middleton, R.J.; Briddon, S.J.; Cordeaux, Y.; Yates, A.S.; Dale, C.L.; George, M.W.; Baker, J.G.; Hill, S.J.; Kellam, B. New fluorescent adenosine A1-receptor agonists that allow quantification of ligand-receptor interactions in microdomains of single living cells. J. Med. Chem. 2007, 50, 782-793.
40. Berque-Bestel, I.; Soulier, J.L.; Giner, M.; Rivail, L.; Langlois, M.; Sicsic, S. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors. J. Med. Chem. 2003, 46, 2606-2620.
41. Joubert, J.; Van Dyk, S.; Green, I.R.; Malan, S.F. Synthesis, evaluation and application of polycyclic fluorescent analogs as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands. Eur. J. Med. Chem. 2011, 46, 5010-5020.
42. Vázquez, M.E.; Blanco, J.B.; Salvadori, S.; Trapella, C.; Argazzi, R.; Bryant, S.D.; Jinsmaa, Y.; Lazarus, L.H.; Negri, L.; Giannini, E.; Lattanzi, R.; Colucci, M.; Balboni, G. 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta-and mu-selective opioid peptides. J. Med. Chem. 2006, 49, 3653-3658.
43. Krieger, F.; Mourot, A.; Araoz, R.; Kotzyba-Hibert, F.; Molgó, J.; Bamberg, E.; Goeldner, M.; Fluorescent agonists for the Torpedo nicotinic acetylcholine receptor. Chembiochem. 2008, 9, 1146-11146.
44. Tam, J.M.; Upadhyay, R.; Pittet, M.J.; Weissleder, R.; Mahmood, U. Improved in vivo whole-animal detection limits of green fluorescent protein-expressing tumor lines by spectral fluorescence imaging. Mol. Imaging. 2007, 6(4), 269-276.
45. Wang, Y.; Mathis, C.A.; Huang, G.F.; Debnath, M.L.; Holt, D.P.; Shao, L.; Klunk, W.E. Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives. J. Mol. Neurosci. 2003, 20(3), 255-260.
46. Middleton, R.J.; Kellam, B. Fluorophore-tagged GPCR ligands. Curr. Opin. Chem. Biol. 2005, 9, 517-525.
47. Rademaker, B.; Kramer, K.; Bast, A.; Timmerman, H. Irreversible binding of the fluorescent beta-adrenoceptor probes alprenolol-NBD and pindolol-NBD to specific and non-specific binding sites. Res. Commun. Chem. Pathol. Pharmacol. 1988, 60, 147-159.
48. Ralevic, V.R.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev., 1998, 50, 413-492.
49. Gomes, C.V.; Kaster, M.P.; Tomé, A.R.; Agostinho, P.M.; Cunha R.A. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochimica. Et. Biophysica. Acta. 2011, 1808, 1380-1399.
50. Macchia, M.; Bertini, S.; Di Bussolo, V.; Manera, C.; Martini, C.; Minutolo, F.; Mori, C.; Saccomanni, G.; Tuscano, D.; Ferrarini, P.L.; 4-[6-(Dansylamino)hexylamino]-7-methyl-2-phenyl-1,8-naphthyridine as a new potential fluorescent probe for studying A1-adenosine receptor. Il. Farmaco. 2002, 57(10), 783-786.
51. Langlois, M.; Fischmeister, R. 5-HT4 receptor ligands: applications and new prospects. J. Med. Chem. 2003, 46, 1-26.
52. Robert, S.J.; Zugara, J.L.; Fischmeister, R.; Gardier, A.M.; Lezoualc'h, F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 2001, 276, 44881-44888.
53. Alonso, D.; Vazquez-Villa, H.; Gamo, A.M.; Martínez-Esperon, M.F.; Tortosa, M.; Viso, A.; de la Pradilla, R.F.; Junquera, E.; Aicart, E.; Martín-Fontecha, M.; Benhamu, B.; Lopez-Rodríguez, M.L.; Ortega-Gutierrez, S. Development of Fluorescent Ligands for the Human 5-HT 1A Receptor. Med. Chem. Lett. 2010, 1, 249-253.
54. Kemp, J.A.; McKernan, R.M. NMDA receptor pathways as drug targets. Nat. Neurosci. 2002, 5, 1039-1042.
55. Cano-Abad, M.F.; Villarroya, M.; García, A.G.; Gabilan, N.H.; Manuela, G., López, M.G. Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death. J. Biol. Chem. 2001, 276, 39695-39704.
56. McCabe, R.T.; Mahan, D.R.; Smith, R.B.; Wamsley, J.K. Characterization of [3H]alprazolam binding to central benzodiazepine receptors. Pharmacol. Biochem. Behav. 1990, 37, 365-370.
57. Geldenhuys, W.J.; Malan, S.F.; Murugensan, T.; Van Der Schyf, C.J. Synthesis and biological evaluation of pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane derivatives as potential therapeutic agents in Parkinson's disease. Bioorg. Med. Chem. 2004, 12, 1799-1806.
58. Shaw, C.A.; Pasqualotto, B.A.; Curry, K.; Kim, S.U.; LeCompte, K.A.; Langmuir, M.E. A novel fluorescent GSH-adduct binds to the NMDA receptor. J. Neurosci. Meth. 1999, 93, 21-26.
59. Thomas, D.D.; Ridnour, L.A.; Isenberg, J.S.; Flores-Santana, W.; Switzer, C.H.; Donzelli, S.; Hussain, S.P.; Vecoli, C.; Paolocci, N.; Ambs, S.; Colton, C.A.; Harris, C.C.; Roberts, D.D.; Wink, D.A. The chemical biology of nitric oxide: implications in cellular signaling. Free. Radical. Biol. Med. 2008, 45(1), 18-31.
60. Moncada, S.; Palmer, R.M.; Higgs, E.A. Pharmacol. Rev. Nitric oxide: physiology, pathophysiology, and pharmacology. 1991, 43(2), 109-142.
61. Lim, M.H.; Lippard, S.J. Fluorescent nitric oxide detection by copper complexes bearing anthracenyl and dansyl fluorophore ligands. Inorg. Chem. 2006, 45, 8980-8989.
62. Hilderbrand, S.A.; Lim, M.H.; Lippard, S.J. Topics in Fluorescence Spectroscopy; C.D. Geddes, J.R. Lakowicz, Eds.; Springer: New York, 2005; pp 163-188.
63. Nagano, T.; Yoshimura, T. Bioimaging of nitric oxide. Chem. Rev. 2002, 102, 1235-1270.
64. Joubert, J.; van Dyk, S.; Malan, S.F. Fluorescent polycyclic ligands for nitric oxide synthase (NOS) inhibition. Bioorg. Med. Chem. 2008, 16, 8952-8958.
65. Larson, A.A.; Kovacs, K.J.; Cooper, J.C.; Kitto, K.F. Transient changes in the synthesis of nitric oxide result in long-term as well as short-term changes in acetic acid-induced writhing in mice. Pain. 2000, 86, 103-111.
66. Southan, G.J.; Szabó, C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol., 1996, 51(4), 383-394.
67. James, M.L.; Selleri, S.; Kassiou, M. Development of ligands for the peripheral benzodiazepine receptor. Curr. Med. Chem. 2006, 13, 1991-2001.
68. Casellas, P.; Galiegue, S.; Basile A.S. Neurochem. In. Peripheral benzodiazepine receptors and mitochondrial function. 2002, 40, 475-486.
69. Papadopoulos, V.; Lecanu, L.; Brown, R.C.; Han, Z.; Yao, Z.X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neurosci. 2006, 138, 749-756.
70. Kozikowski, A.P.; Kotoula, M.; Ma, D.; Boujrad, N.; Tuckmantel, W.; Papadopoulos, V. Synthesis and biology of a 7-nitro-2,1,3-benzoxadiazol-4-yl derivative of 2-phenylindole-3-acetamide: a fluorescent probe for the peripheral-type benzodiazepine receptor. J. Med. Chem. 1997, 40(16), 2435-2439.
71. Taliani, S.; Simorini, F.; Sergianni, V.; La Motta, C.; Da Settimo, F.; Cosimelli, B.; Abignente, E.; Greco, G.; Novellino, E.; Rossi, L.; Gremigni, V.; Spinetti, F.; Chelli, B.; Martini, C. New fluorescent 2-phenylindolglyoxylamide derivatives as probes targeting the peripheral-type benzodiazepine receptor: design, synthesis, and biological evaluation. J. Med. Chem. 2007, 50, 404-407.
72. Primofiore, G.; Da Settimo, F.; Taliani, S.; Simorini, F.; Patrizi, M.P.; Novellino, E.; Greco, G.; Abignente, E.; Costa, B.; Chelli, B.; Martini C. N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor. J. Med. Chem. 2004, 47, 1852-1855.
73. Joyce, J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 2001, 90, 231-259.
74. Joyce, J.N.; Millan, M.J. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr Opin Pharmacol, 2007, 7, 100-105.
75. Leopoldo, M.; Lacivita, E.; Passafiume, E.; Contino, M.; Colabufo, N.A.; Berardi, F.; Perrone, R. 4-[omega-[4-arylpiperazin-1-yl]alkoxy]phenyl)imidazo[1,2-a]pyridine derivatives: fluorescent high-affinity dopamine D3 receptor ligands as potential probes for receptor visualisation. J. Med. Chem. 2007, 50(20), 5043-5047.
76. Rasmussen, S.G.F.; Carroll, F.I.; Maresch, M.J.; Jensen, A.D.; Tate, C.G.; Gether, U. Biophysical characterization of the cocaine binding pocket in the serotonin transporter using a fluorescent cocaine analog as a molecular reporter. J. Biol. Chem. 2001, 276, 4717-4723.
77. Lancet, D.; Pecht, I. Spectroscopic and immunochemical studies with nitrobenzoxadiazolealanine, a fluorescent dinitrophenyl analog. Biochem. 1977, 16, 5150-5157.
78. Meijler, M.M.; Kaufmann, G.F.; Qi, L.; Mee, J.M.; Coyle, A.R.; Moss, J.A.; Wirsching, P.; Matsushita, M.; Janda, K.D. Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies. J. Am. Chem. Soc. 2005, 127, 2477-2484.
79. Cha, J.H.; Zou, M.; Adkins, E.M.; Rasmussen, S.G.F.; Schoenenberger, C.J.L.B. Gether, U.; Newman, A.H. Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogs as high-affinity fluorescent probes for the dopamine transporter. J. Med. Chem. 2005, 48, 7513-7516.
80. Lakovicz, J.R. Principles of Fluorescence Spectroscopy; Kluwer Academic/Plenum Publishers: New York, 1999.
81. Bermack, J.E.; Debonnel, G. The role of sigma receptors in depression. J. Pharmacol. Sci. 2005, 97, 317-336.
82. Fishback, J.A.; Robson, M.J.; Xu, Y.T.; Matsumoto, R.R. Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol. Ther. 2010, 127, 271-282.
83. Wang, J.; Mack, A.L.; Coop, A.; Matsumoto, R.R. Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice. Eur. Neuropsychopharmacol. 2007, 17, 708-716.
84. Nguyen, E.C.; McCracken, K.A.; Liu, Y.; Pouw, B.; Matsumoto, R.R. Involvement of sigma receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology. 2005, 49, 638-645.
85. Matsumoto, R.R.; Liu, Y.; Lerner, M.; Howard, E.W.; Brackett, D.J. Sigma receptors: potential medications development target for anti-cocaine agents. Eur. J. Pharmacol. 2003, 469, 1-12.
86. Collier, T.L.; Waterhouse, R.N.; Kassiou, M. Imaging sigma receptors: applications in drug development. Curr. Pharm. 2007, 13, 51-72.
87. Kassiou, M.; Dannals, R.F.; Liu, X.; Wong, D.F.; Ravert, H.T.; Scheffel, U.A. Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors. Bioorg. Med. Chem. 2005, 13, 3623-3626.
88. Zeng, C.; Vangveravong, S.; Xu, J.; Chang, J.C.; Hotchkiss, R.S.; Wheeler, K.T.; Shen, D.; Zhuang, Z.P.; Kung, H.F.; Mach, R.H. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer. Res. 2007, 67, 6708-6716.
89. Vangveravong, S.; Xu, J.; Zeng, C.; Mach R.H. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands. Bioorg. Med. Chem. 2006, 14, 6988-6997.
90. Hyman, B.T.; Trojanowski, J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997, 56(10), 1095-1097.
91. Goedert, M.; Spillantini, M.G. A century of Alzheimer's disease. Science. 2001, 314, 777-781.
92. Raymond, S.B.; Skoch, J.; Hills, I.D.; Nesterov, E.E.; Timothy, M.; Swager, M.; Bacskai B.J. Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology. Eur. J. Nucl. Med. Mol. Imaging. 2008, 35, S93-S98.
93. Ojida, A.; Sakamoto, T.; Inoue, M.; Fujishima, S.; Lippens, G.; Hamachi I. Fluorescent BODIPY-based Zn(II) complex as a molecular probe for selective detection of neurofibrillary tangles in the brains of Alzheimer's disease patients. J. Am. Chem. Soc. 2009, 131(18), 6543-6548.
94. Poduslo, J.F.; Wengenack, T.M.; Curran, G.L.; Wisniewski, T.; Sigurdsson, E.M.;. Macura, S.I.; Borowski, B.J.; Jack, C.R. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 2002, 11(2), 315-29.
95. Higuchi, M.; Iwata, N.; Matsuba, Y.; Sato, K.; Sasamoto, K.; Saido, T.C. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 2005, 8(4), 527-533.
96. Shoghi-Jadid, K.; Small, G.W.; Agdeppa, E.D.; Kepe, V.; Ercoli, L.M.; Siddarth, P.; Read, S.; Satyamurthy, N.; Petric, A.; Huang, S.C.; Barrio, J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry. 2002, 10(1), 24-35.
97. Ono, M.; Wilson, A.; Nobrega, J.; Westaway, D.; Verhoeff, P.; Zhuang, Z.P.; Kung, M.P.; Kung, H.F. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl. Med. Biol. 2003, 30(6), 565-571.
98. Klunk, W.E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D.P.; Bergström, M.; Savitcheva, I.; Huang, G.F.; Estrada, S.; Ausén, B.; Debnath, M.L.; Barletta, J.; Price, J.C.; Sandell, J.; Lopresti, B.J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C.A.; Långström, B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55(3), 306-319.
99. Hintersteiner, M.; Enz, A.; Frey, P.; Jaton, A.L.; Kinzy, W.; Kneuer, R.; Neumann, U.; Rudin, M.; Staufenbiel, M.; Stoeckli, M.; Wiederhold, K.H.; Gremlich, H.U. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol. 2005, 23(5), 577-583.
100. Nesterov, E.E.; Skoch, J.; Hyman, B.T.; Klunk, W.E.; Bacskai, B.J.; Swager, T.M. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew. Chem. Int. Ed. Engl. 2005, 44(34), 5452-5456.
101. Becker, A.; Hessenius, C.; Licha, K.; Ebert, B.; Sukowski, U.; Semmler, W.; Wiedenmann, B.; GrItzinger, C. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat. Biotechnol. 2001, 19, 327-331.
102. Bai, M.; Sexton, M.; Stella, N.; Bornhop, D.J. MBC94, a conjugable ligand for cannabinoid CB 2 receptor imaging. Bioconjug. Chem. 2008, 19, 988-992.
103. Hadrich, D.; Berthold, F.; Steckhan, E.; Bonisch, H. Synthesis and characterization of fluorescent ligands for the norepinephrine transporter: potential neuroblastoma imaging agents. J. Med. Chem. 1999, 42, 3101-3108.
104. Brown, A.S.; Bernal, L.; Micotto, T.L.; Smith, E.L.; Wilson, J.N. Fluorescent neuroactive probes based on stilbazolium dyes. Org. Biomol. Chem. 2011, 9, 2142-2148.
105. Mamelak, A.N.; Jacoby, D.B. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Exp. Opin. Drug. Deliv. 2007, 4(2), 175-186.
106. "Fluorescent cancer cells to guide brain surgeons." PHYSorg.com. 3 Apr 2009. www.physorg.com/news157976452.html
107. Kremer, P.; Fardanesh, M.; Ding, R.; Pritsch, M.; Zoubaa, S.; Frei, E. Neurosurgery 2009, DOI:10.1227/01.NEU.0000335787.17029.67.